Probiodrug

Fred Rosche

Hans-Ulrich Demuth

Torsten Hoffmann

Robert P Pauly

Joem Schmidt

Christopher H S McIntosh

Ray A Pederson

A method of raising the blood sugar level in a mammal having hypoglycemia is described. The method reduces degradation of glucagon by administering to the mammal a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV and physiologically acceptable adjuvants and/or excipients.

Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV

Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.

Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals

Growing community of inventors

Halle/Saale, Germany

Fred Rosche